Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

5-hydroxytryptamine medications for the treatment of obesity.

Burke LK, Heisler LK.

J Neuroendocrinol. 2015 Jun;27(6):389-98. doi: 10.1111/jne.12287. Review.

PMID:
25925636
2.

From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists.

Higgins GA, Sellers EM, Fletcher PJ.

Trends Pharmacol Sci. 2013 Oct;34(10):560-70. doi: 10.1016/j.tips.2013.08.001. Epub 2013 Sep 13. Review.

PMID:
24041919
3.

Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).

Yang Y, An S, Liu Y, Guo XX, Gao L, Wei JF, Xu TR.

Expert Opin Ther Pat. 2016;26(1):89-106. doi: 10.1517/13543776.2016.1113257. Epub 2015 Nov 26. Review.

PMID:
26609882
4.

Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders.

Higgins GA, Fletcher PJ.

ACS Chem Neurosci. 2015 Jul 15;6(7):1071-88. doi: 10.1021/acschemneuro.5b00025. Epub 2015 Apr 14. Review.

PMID:
25870913
5.

Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype-targeted drugs.

Meltzer HY, Roth BL.

J Clin Invest. 2013 Dec;123(12):4986-91. doi: 10.1172/JCI70678. Epub 2013 Dec 2. Review.

6.

Increased alternate splicing of Htr2c in a mouse model for Prader-Willi syndrome leads disruption of 5HT2C receptor mediated appetite.

Garfield AS, Davies JR, Burke LK, Furby HV, Wilkinson LS, Heisler LK, Isles AR.

Mol Brain. 2016 Dec 8;9(1):95.

7.

The safety and efficacy of lorcaserin in the management of obesity.

Hess R, Cross LB.

Postgrad Med. 2013 Nov;125(6):62-72. doi: 10.3810/pgm.2013.11.2713. Review.

PMID:
24200762
8.

Lorcaserin for the treatment of obesity.

Redman LM, Ravussin E.

Drugs Today (Barc). 2010 Dec;46(12):901-10. doi: 10.1358/dot.2010.46.12.1556433. Review.

9.

Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel?

Miller KJ, Wacker DA.

Future Med Chem. 2010 Dec;2(12):1761-75. doi: 10.4155/fmc.10.261.

PMID:
21428799
10.

5-HT(2C) receptor agonists and the control of appetite.

Halford JC, Harrold JA.

Handb Exp Pharmacol. 2012;(209):349-56. doi: 10.1007/978-3-642-24716-3_16. Review.

PMID:
22249823
11.

Lorcaserin: an investigational serotonin 2C agonist for weight loss.

Hurren KM, Berlie HD.

Am J Health Syst Pharm. 2011 Nov 1;68(21):2029-37. doi: 10.2146/ajhp100638. Review.

PMID:
22011982
12.

5-HT obesity medication efficacy via POMC activation is maintained during aging.

Burke LK, Doslikova B, D'Agostino G, Garfield AS, Farooq G, Burdakov D, Low MJ, Rubinstein M, Evans ML, Billups B, Heisler LK.

Endocrinology. 2014 Oct;155(10):3732-8. doi: 10.1210/en.2014-1223. Epub 2014 Jul 22.

13.

Central serotonin and melanocortin pathways regulating energy homeostasis.

Heisler LK, Cowley MA, Kishi T, Tecott LH, Fan W, Low MJ, Smart JL, Rubinstein M, Tatro J, Zigman JM, Cone RD, Elmquist JK.

Ann N Y Acad Sci. 2003 Jun;994:169-74. Review.

PMID:
12851313
14.

Serotonergic anti-obesity agents: past experience and future prospects.

Halford JC, Boyland EJ, Lawton CL, Blundell JE, Harrold JA.

Drugs. 2011 Dec 3;71(17):2247-55. doi: 10.2165/11596680-000000000-00000. Review.

PMID:
22085383
15.

Urocortin1-induced anorexia is regulated by activation of the serotonin 2C receptor in the brain.

Harada Y, Takayama K, Ro S, Ochiai M, Noguchi M, Iizuka S, Hattori T, Yakabi K.

Peptides. 2014 Jan;51:139-44. doi: 10.1016/j.peptides.2013.11.009. Epub 2013 Nov 21.

16.

Nucleus of the Solitary Tract Serotonin 5-HT2C Receptors Modulate Food Intake.

D'Agostino G, Lyons D, Cristiano C, Lettieri M, Olarte-Sanchez C, Burke LK, Greenwald-Yarnell M, Cansell C, Doslikova B, Georgescu T, Martinez de Morentin PB, Myers MG Jr, Rochford JJ, Heisler LK.

Cell Metab. 2018 Oct 2;28(4):619-630.e5. doi: 10.1016/j.cmet.2018.07.017. Epub 2018 Aug 23.

17.

ACS chemical neuroscience molecule spotlight on Lorcaserin.

Hopkins CR.

ACS Chem Neurosci. 2010 Nov 17;1(11):718-9. doi: 10.1021/cn100059u. Review.

18.

Lorcaserin improves glycemic control via a melanocortin neurocircuit.

Burke LK, Ogunnowo-Bada E, Georgescu T, Cristiano C, de Morentin PBM, Valencia Torres L, D'Agostino G, Riches C, Heeley N, Ruan Y, Rubinstein M, Low MJ, Myers MG, Rochford JJ, Evans ML, Heisler LK.

Mol Metab. 2017 Oct;6(10):1092-1102. doi: 10.1016/j.molmet.2017.07.004. Epub 2017 Jul 21.

19.

Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Nigro SC, Luon D, Baker WL.

Curr Med Res Opin. 2013 Jul;29(7):839-48. doi: 10.1185/03007995.2013.794776. Epub 2013 May 10. Review.

PMID:
23574263
20.

Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways.

Zhou L, Sutton GM, Rochford JJ, Semple RK, Lam DD, Oksanen LJ, Thornton-Jones ZD, Clifton PG, Yueh CY, Evans ML, McCrimmon RJ, Elmquist JK, Butler AA, Heisler LK.

Cell Metab. 2007 Nov;6(5):398-405.

Supplemental Content

Support Center